Company intelligence / Profile preview

Procyon Technologies

Tucson, Arizona, United States

Ownership: Private
Development stage: Other

Overview

Procyon Technologies is developing an oxygen-enabled, implantable encapsulation device to deliver allogeneic or stem cell–derived islet cells subcutaneously as a potential functional cure for type 1 diabetes without systemic immunosuppression; available information describes device engineering, preclinical rationale, and supporting academic work on islet oxygenation and encapsulation, but no human clinical trial results are reported yet.[1][6]

Therapeutic areas: Endocrinology
Modalities: Cell therapyDeviceImplantable medical device
Industry: Biotech

Partnerships

Institute for Cellular Transplantation at the University of Arizona College of Medicine in Tucson[1]Corporate partner for clinical-grade human stem cell derived islets (unnamed)[1]

Beyond the preview

Go deeper on Procyon Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Procyon Technologies.

Explore the full profile